Inflammatory & Systemic Conditions
What was the challenge?
The immune system is central to responding to and mediating inflammatory, systemic or autoimmune conditions. Inflammatory conditions may rise from pathogenic infections, injuries or metabolites from internal dysregulations. Systemic conditions may rise from genetic causes, dysregulated systems or certain intolerances in metabolic pathways. Therapeutics are targeted to neutralise or inhibit acute or chronic immune responses that are associated with innate immune (such as phagocytosis, macrophage polarisation) or specific T-helper pathways (such as Th1, Th2 or Th17).
|differentiated||activated||inhibited||R5 %||R5 MFI||R7 %||R7 MFI|
To test the ability of a compound to inhibit Th17 response in an inflammatory condition.
Approach: in vitro Th17 differentiation assay
We adopted our in-house human Th17 assay to test multiple formulations in a dose-dependent manner for inhibition of a Th17 response. TALL-1 cells differentiated and activated were treated with the formulations and measured for IL-17 and IL-22 by flow cytometry.
Effective formulations were identified and research proceeded to clinical studies.